<DOC>
	<DOCNO>NCT00095225</DOCNO>
	<brief_summary>This Phase II , multicenter , randomize trial design make preliminary evaluation efficacy combine bevacizumab chemotherapy ( docetaxel pemetrexed ) Tarceva relative chemotherapy ( docetaxel pemetrexed ) alone patient previously treat advanced NSCLC .</brief_summary>
	<brief_title>A Study Evaluate Bevacizumab Chemotherapy Tarceva Treating Recurrent Refractory NSCLC ( Non-Small Cell Lung Cancer )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Neoplasm Recurrence , Local</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Signed write informed consent Histologically cytologically proven Stage IIIb pleural effusion , Stage IV , recurrent nonsquamous NSCLC recurrent unresectable Progression one line platinumbased chemotherapy ( patient receive prior docetaxel treatment eligible participate contraindication pemetrexed treatment ) Progression previous adjuvant chemotherapy , therapy complete &gt; = 6 month prior randomization patient receive one line therapy recurrent disease ( Optional ) Availability archival diagnostic tissue ( paraffin tissue block 210 unstained slide representative patient 's primary cancer ) ECOG performance status 0 , 1 , 2 Life expectancy &gt; = 3 month Measurable disease accordance RECIST Age &gt; = 18 year Use acceptable mean contraception ( potentially fertile men woman ) documentation infertility More 30 day prior treatment investigational market agent act EGFR inhibition ( 30 few day EGFR inhibitor without disease progression eligible enrollment ) Treatment investigational market agent act antiangiogenic mechanism Previous treatment one platinumbased chemotherapy Chemotherapy radiotherapy within 28 day prior randomization History hemoptysis ( &amp; gt ; 1 teaspoon ) presence cavitary lesion Clinical history Grade &amp; gt ; 2 hematemesis within 6 month Grade 1 hematemesis within 28 day prior randomization History serious systemic disease , include myocardial infarction within last 6 month , uncontrolled hypertension ( blood pressure &amp; gt ; 150/100 mmHg medication ) , unstable angina , New York Heart Association ( NYHA ) Grade II great congestive heart failure , unstable symptomatic arrhythmia require medication ( patient chronic atrial arrhythmia , i.e. , atrial fibrillation paroxysmal supraventricular tachycardia eligible ) , Grade II great peripheral vascular disease History clinical evidence CNS brain metastasis CNS bleed History clinical evidence hemorrhagic thrombotic stroke within 6 month prior randomization Centrally locate lesion lesion abut major blood vessel Ongoing treatment fulldose warfarin ( equivalent ) heparin ( equivalent ; e.g. , Lovenox ( R ) ) Inpatient surgical procedure , open biopsy , significant traumatic injury within 28 day prior randomization Minor surgical procedure , fine needle aspiration , core biopsy within 7 day prior randomization Anticipation need major surgical procedure course study Serious , nonhealing wound , ulcer , bone fracture Inability take oral medication requirement IV alimentation total parenteral nutrition lipid , prior surgical procedure affect absorption Any follow abnormal hematologic value ( within 1 week prior randomization ) : ANC &lt; = 1,500 cells/uL ; platelet count &lt; = 100,000 cells/uL ; Hemoglobin &lt; = 9.0 g/dL ; International normalize ratio ( INR ) &amp; gt ; 1.5 x upper limit normal ( ULN ) For patient receive docetaxel , follow abnormal liver function test ( within 1 week prior randomization ) : Serum bilirubin great ULN ; Albumin &lt; = 2.5 g/dL ; Serum ALT &gt; = 1.5 x ULN ; Serum AST &gt; = 1.5 x ULN ; Alkaline phosphatase &gt; = 2.5 x ULN Other baseline laboratory value : Serum creatinine &amp; gt ; 2.0 x ULN ; Uncontrolled hypercalcemia ( &amp; gt ; 11.5 mg/dL ) ; Urinary protein/creatinine ratio &gt; = 1 ( spot urine ) clinically significant impairment renal function ; Estimated creatinine clearance &amp; lt ; 45 mL/min ( patient receive pemetrexed ) Any active systemic bacterial , fungal , viral infection , include know hepatitis C HIV Pregnant breastfeed Presence another cancer within 5 year prior randomization , except adequately treat carcinoma situ cervix nonmelanomatous skin cancer Evidence confusion disorientation , history major psychiatric illness may impair patient 's understanding Informed Consent Form</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Recurrent refractory non-small cell lung cancer</keyword>
</DOC>